Alexander Pearson to Antineoplastic Agents
This is a "connection" page, showing publications Alexander Pearson has written about Antineoplastic Agents.
Connection Strength
0.529
-
Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010). Clin Cancer Res. 2023 12 01; 29(23):4751-4759.
Score: 0.106
-
Clinical trials of immunotherapy in triple-negative breast cancer. Breast Cancer Res Treat. 2022 Aug; 195(1):1-15.
Score: 0.096
-
The Endothelin-A Receptor Antagonist Zibotentan Induces Damage to the Nasal Olfactory Epithelium Possibly Mediated in Part through Type 2 Innate Lymphoid Cells. Toxicol Pathol. 2019 02; 47(2):150-164.
Score: 0.075
-
Ablation of Cancer Stem Cells by Therapeutic Inhibition of the MDM2-p53 Interaction in Mucoepidermoid Carcinoma. Clin Cancer Res. 2019 03 01; 25(5):1588-1600.
Score: 0.075
-
A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer. Invest New Drugs. 2016 08; 34(4):481-9.
Score: 0.063
-
Targeting MDM2 for Treatment of Adenoid Cystic Carcinoma. Clin Cancer Res. 2016 07 15; 22(14):3550-9.
Score: 0.062
-
Machine learning can identify newly diagnosed patients with CLL at high risk of infection. Nat Commun. 2020 01 17; 11(1):363.
Score: 0.020
-
Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer. Clin Cancer Res. 2017 Sep 15; 23(18):5561-5572.
Score: 0.017
-
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer. Cancer Res. 2016 04 15; 76(8):2301-13.
Score: 0.016